Nebivolol Combix

Nebivolol, the active ingredient in Nebivolol Combix, is a beta blocker presented as an oral tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Nebivolol Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used primarily in the management of cardiovascular conditions.

Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and heart attack. Heart Failure: improves left‑ventricular ejection fraction and symptoms in patients with mild to moderate chronic heart failure.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nasal congestion or sinus discomfort. - Diarrhea or mild gastrointestinal upset. - Reduced exercise tolerance.

Serious or Rare Side Effects: - Bradycardia: heart rate markedly below normal. - Severe hypotension: sudden, significant drop in blood pressure. - Acute heart failure decompensation. - Bronchospasm in patients with reactive airway disease. - Allergic reactions such as rash, itching, or angioedema. - Liver enzyme elevations indicating hepatic stress.

Before initiating therapy, clinicians should evaluate patient history and comorbidities. - Cardiovascular assessment: review for bradyarrhythmias, heart block, or decompensated heart failure. - Renal function: adjust use in severe renal impairment. - Hepatic status: monitor liver enzymes in patients with liver disease. - Concomitant medications: assess for drugs that also lower heart rate or blood pressure. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels. - Non‑selective beta blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): heightened risk of AV block.

Moderate Interactions (Monitor Closely):\n- Diuretics: may potentiate hypotensive effects. - Antihypertensive agents (ACE inhibitors, ARBs): monitor for excessive blood pressure reduction. - Antidepressants (SSRIs, SNRIs): observe for synergistic heart‑rate lowering.